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Abstract
The role of mammalian high temperature requirement protease A1 (HTRA1) in somatic
stem cell differentiation and mineralized matrix formation remains controversial, having
been demonstrated to impart either anti- or pro-osteogenic effects, depending on the in
vitro cell model used. The aim of this study was therefore to further evaluate the role of
HTRA1 in regulating the differentiation potential and lineage commitment of murine mes-
enchymal stem cells in vitro, and to assess its influence on bone structure and regenera-
tion in vivo. Our results demonstrated that short hairpin RNA-mediated ablation of Htra1 in
the murine mesenchymal cell line C3H10T1/2 increased the expression of several osteo-
genic gene markers, and significantly enhanced matrix mineralization in response to
BMP-2 stimulation. These effects were concomitant with decreases in the expression of
chondrogenic gene markers, and increases in adipogenic gene expression and lipid
accrual. Despite the profound effects of loss-of-function of HTRA1 on this in vitro osteo-
chondral model, these were not reproduced in vivo, where bone microarchitecture and
regeneration in 16-week-old Htra1-knockout mice remained unaltered as compared to
wild-type controls. By comparison, analysis of femurs from 52-week-old mice revealed
that bone structure was better preserved in Htra1-knockout mice than age-matched wild-
type controls. These findings therefore provide additional insights into the role played by
HTRA1 in regulating mesenchymal stem cell differentiation, and offer opportunities for
improving our understanding of how this multifunctional protease may act to influence
bone quality.
Introduction
Mammalian high temperature requirement protease A1 (HTRA1) is one of four HtrA serine
protease family members [1, 2], having recently come into prominence by virtue of its pre-
dicted involvement in the genetic disorders age-related macular degeneration (AMD) [3, 4]
PLOS ONE | https://doi.org/10.1371/journal.pone.0181600 July 21, 2017 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Filliat G, Mirsaidi A, Tiaden AN, Kuhn GA,
Weber FE, Oka C, et al. (2017) Role of HTRA1 in
bone formation and regeneration: In vitro and in
vivo evaluation. PLoS ONE 12(7): e0181600.
https://doi.org/10.1371/journal.pone.0181600
Editor: Gianpaolo Papaccio, Università degli Studi
della Campania "Luigi Vanvitelli", ITALY
Received: May 19, 2017
Accepted: July 3, 2017
Published: July 21, 2017
Copyright: © 2017 Filliat et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This study was supported by grants from
the Swiss National Science Foundation
(31003A_156313), Swiss Life, and the Foundation
for Research in Science and Humanities at the
University of Zurich.
Competing interests: The authors have declared
that no competing interests exist.
and cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopa-
thy (CARASIL) [5, 6]. HTRA1, like its three paralogs, contains a trypsin-like protease domain
and one PDZ domain [7]. At the amino acid level, HTRA1 shares highest identity with
HTRA3 [8]. Furthermore, both HTRA1 and HTRA3 have been detected at comparable loca-
tions both in mice and humans [9, 10]. Although primarily regarded as a secreted protease,
HTRA1 has been detected in several different subcellular locations [11–13], thus providing
alternative routes through which it may influence biological processes. In this regard, HTRA1
has amassed an impressive collection of substrates, including both intracellular (e.g. tuberous
sclerosis complex 2, tubulins, tau, and proTGF-β1) [11–14] and extracellular (e.g. bone sialo-
protein, fibronectin, elastin, fibromodulin, TGF-β1) [15–19] proteins. Subsequently, interest
in HTRA1’s contribution to human development and disease is wide ranging, encompassing
numerous research fields such as cancer [20, 21], reproduction [22, 23], neurology [17, 24],
and the musculoskeletal system [25].
Findings from our previous studies and from others, have identified HTRA1 as an impor-
tant factor in determining the lineage commitment of primary mesenchymal stem cells
(MSCs), where it acted to promote osteogenesis at the expense of adipogenesis [15, 26–28]. In
support of this, HTRA1 protein has been detected in developing bones in vivo, as well as in
fracture callus [9, 15, 19]. However, in contrast to these findings, several studies now exist in
which HTRA1 has been demonstrated to impart a negative influence over osteogenesis [29,
30]. Although the cause of these conflicting results remains unclear, it is important to note that
inherent differences exist between the cell culture systems used in each of these studies, and
may therefore indicate that cell specific effects of HTRA1 need to be taken into account. In fur-
ther support of HTRA1’s role in repressing osteogenesis, studies using Htra1-knockout mice
demonstrated significant improvements in a small number of bone parameters at selected skel-
etal sites [31]. However, these findings are confounded by the apparent lack of any skeletal
aberrations in HTRA1 deficient mice generated by other investigators [32]. Clearly therefore,
HTRA1’s regulation of bone formation remains a controversial issue and as such, requires fur-
ther investigation.
In the current study, we have assessed the role of HTRA1 in regulating osteogenesis in vitro
and in vivo. We determined the effects of loss-of-function of HTRA1 on the differentiation
potential of C3H10T1/2 cells stimulated with BMP-2, and on bone development and regenera-
tion in mice. We demonstrated that matrix mineralization was significantly enhanced in
HTRA1 deficient C3H10T1/2 cells, in association with the increased expression of several oste-
ogenic gene markers. In addition, adipogenesis was also enhanced in HTRA1 deficient
C3H10T1/2 cells, whilst chondrogenic gene expression was downregulated. By contrast,
HTRA1 deficiency had no effect on the bone microarchitecture or regeneration of femurs
from 16-week-old mice, although bone structure in aged mice was significantly improved as
compared to age-matched wild-type controls.
Materials and methods
Materials
Human recombinant bone morphogenetic protein-2 (hrBMP-2) was prepared as previously
reported [33]. Polyclonal rabbit anti-HTRA1 and anti-HTRA3 were generously provided by
Prof. Michael Ehrmann (University of Duisburg-Essen, Germany) [24, 34] and Prof. Chio Oka
(NAIST, Japan) [9]. Biotinylated swine anti-rabbit IgG (E0431) was purchased from Dako
(Baar, Switzerland).
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Cell culture and differentiation
C3H10T1/2 cell line. The murine mesenchymal cell line C3H10T1/2 [35] was kindly pro-
vided by Dr. Ronald Biemann (University of Magdeburg, Germany). Cells were cultured in
normal growth medium consisting of Dulbecco’s modified eagle medium (DMEM-low glu-
cose, with GlutaMAX; Thermo Fisher Scientific, Reinach, Switzerland), supplemented with
10% foetal bovine serum (FBS; Sigma-Aldrich, Buchs, Switzerland), and penicillin/streptomy-
cin (50 units/ml; 50 μg/ml; Thermo Fisher Scientific). For differentiation studies, cells were
seeded at a density of 7’000 cells/cm2 and cultured in osteogenic induction medium consisting
of normal growth medium supplemented with 10 mM β-glycerophosphate (Sigma-Aldrich),
50 μM L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma-Aldrich) and
hrBMP-2 (100 ng/ml) for up to 49 days with regular medium changes.
Lentiviral shRNA
Lentiviral shRNA constructs specific for Htra1 were purchased from the Sigma Mission library
(Sigma-Aldrich) and consisted of TRCN0000031484 (shHtra184) and TRCN0000031486
(shHtra186). The SHC002 non-target control shRNA construct (shControl) was kindly pro-
vided by Prof. Michael Ehrmann (University of Duisburg-Essen, Germany). All shRNA con-
struct were cloned into the pLKO.1-puro vector. In order to generate shRNA-expressing
lentiviral particles, HEK293T cells were transfected with shRNA plasmids, in combination
with packaging plasmid pCD/NL-BHDDD (Addgene plasmid #17531) [36] and envelope
plasmid pLTR-G (Addgene #17532) [37] using calcium phosphate co-precipitation, and lenti-
viral particles collected at 24 and 48 h. C3H10T1/2 cell cultures were transduced with virus,
together with 8 μg/ml polybrene (Sigma-Aldrich), and medium refreshed with normal growth
medium after 24 h. Transduced cells were selected for 1 week in the presence of 2 μg/mL puro-
mycin (Sigma Aldrich), and subsequently seeded at 7’000 cells/cm2 in cell culture plates.
RT-qPCR
Reverse-transcription quantitative PCR (RT-qPCR) was performed using TaqMan Gene
Expression Assays (Thermo Scientific) (S1 Table) as previously described [27]. Briefly, a total
of 0.5 μg of RNA was reverse-transcribed using Superscript II (Thermo Scientific), and suc-
cessive qPCR reactions performed using the StepOnePlus (Thermo Scientific). Values were
normalized to Rps12 mRNA levels and presented as fold change according to the 2-ΔΔCT
method.
Animals
Mice with targeted mutations in Htra1 were generated using homologous recombination as
previously described [38]. Mice were housed in groups of two to five animals under specific
pathogen free conditions, and were allowed to acclimatize for one week prior to surgery.
Housing rooms were maintained on a light/dark cycle of 12/12 h with artificial light, and ani-
mals were fed a commercial diet and water ad libitum. All surgeries were performed under
aseptic conditions using isoflurane anaesthesia, and post-operative pain controlled using
Buprenorphine. Mice were euthanized by cervical dislocation following isoflurane-induced
anaesthesia. All procedures were approved by the Veterinary Office of the Canton of Zurich,
Switzerland (Project License 262/2014 and 197/2013) and were carried out in strict accordance
with the guidelines of the Swiss Federal Veterinary Office for the use and care of laboratory
animals.
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Femoral osteotomy model
A femoral osteotomy model was performed in wild-type (WT) (n = 62) and Htra1-knockout
(Htra1-KO) (n = 61) female mice (16 weeks-of-age) using previously established protocols [39,
40]. The mean weights of WT (22.7 g ± 1.5) and Htra1-KO (23.2 g ± 1.8) mice were not signifi-
cantly different at the time of surgery, and animals were randomly assigned to experimental
groups. Mice were injected subcutaneously with Buprenorphine (Temgesic1 solution, 0.3 mg/
mL; Reckitt Benckiser, Wallisellen, Switzerland) at a dose of 0.1 mg/kg 30 min prior to surgery,
and subsequently placed under general anaesthesia using 2% isoflurane and 100% oxygen as a
carrier at 400 ml/min. Eye cream was administered to the eyes to prevent drying out. The skin
was incised over the lateral aspect of the thigh and a flexible or rigid 4 hole MouseFix plate
(RISystem, Davos, Switzerland) secured to the anterolateral aspect of the femur using inter-
locking screws. A Gigli saw (0.22 mm) was then used to create a mid diaphyseal osteotomy gap
with the assistance of a saw guide. The osteotomy site was then irrigated with sterile saline, and
the incision closed using Vicryl 6–0 (Ethicon, Norderstedt, Germany) and Appose ULC 35W
skin staples (Medtronic, Muenchenbuchsee, Switzerland). Betadine was applied topically to
the wound as a preventative measure against possible infection. Post-operative pain was con-
trolled using Buprenorphine (1 mg/kg via drinking water) ad libitum for the first 4 days, and
animal health and well-being monitored and recorded using a comprehensive scoring system
every 12 h for the first 3 days, and then three times per week for the remainder of the study.
Anaesthetized mice were euthanized at 10, 14, 21 and 35 days after surgery (n = 8–13 mice/
group/time point) by cervical dislocation, and femurs harvested for further analysis.
Micro-CT analysis of mouse femurs
Following the removal of surrounding soft tissue, mouse femurs were fixed in 4% formalde-
hyde in phosphate buffered saline (PBS, pH 7.4) for 24 h at 4˚C. Bones were then extensively
washed in running tap water and stored in 70% ethanol until analysed. Comparisons of bone
structure in intact femurs were performed between 16-week-old WT (n = 8), Htra1-heterozy-
gous (Htra1-HET) (n = 8), and Htra1-KO (n = 7) mice; 52-week-old WT (n = 8) and Htra1-
KO (n = 6) mice. Femurs were scanned on a microCT40 (Scanco Medical AG, Bru¨ttisellen
Switzerland) operated at 55 kVp and 145 μA with 200 ms integration time and 2-fold frame
averaging. Images were reconstructed from 1000 projections at a nominal isotropic resolution
of 10 μm. After application of a Gaussian Filter (sigma 0.8, support 1), image thresholds were
set, and automated masks of full bone, cortex and metaphyseal trabecular bone created
[41, 42].
Evaluation of bone volume in osteotomy sites stabilized with a flexible MouseFix plate was
performed in WT and Htra1-KO mice at 21 days (WT, n = 11; Htra1-KO, n = 10) and 35 days
(WT, n = 10; Htra1-KO, n = 13) post-surgery. Analysis of osteotomy sites stabilized with a
rigid MouseFix plate was performed in WT and Htra1-KO mice at 21 days (WT, n = 9; Htra1-
KO, n = 9) post-surgery. Following removal of the MouseFix plate, micro-CT measurements
were performed using the same settings as the intact femurs described above. After image pro-
cessing, a threshold of 25% of maximum grey value was applied, and a volume of interest (500
x 500 x 280 voxels) manually selected to accommodate the full callus volume between the
inner screws in which the volume of mineralized tissue was calculated (S1 Fig). We chose not
to distinguish between original and newly formed bone as no reliable thresholds could be
determined. Analysis of osteotomy repair was not performed in cases where the MouseFix
plates failed to attach correctly during surgery (WT, n = 6; Htra1-KO, n = 7), or showed signs
of loosening or dislocation at the time of harvesting (WT, n = 4; Htra1-KO, n = 4).
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Histological staining of C3H10T1/2 cell cultures
Alizarin Red S. Matrix mineralization was assessed using Alizarin Red S staining as previ-
ously described [27]. Cells were washed in phosphate buffered saline (PBS) and fixed in 4%
formaldehyde in PBS (pH 7.4) for 1 h at room temperature. Cells were then washed in water
and stained with 2% Alizarin Red S (pH 4.2) for 10 min at room temperature. Cells were subse-
quently washed in PBS, and images captured using a digital camera (Canon EF-S18-55IS2).
Alizarin Red S was then extracted in 10% cetylpyridinium chloride (Sigma-Aldrich), and opti-
cal densities measured at 570 nm using an Infinite M200 multiplate reader (Tecan) and nor-
malized to cell number as previously described [27].
Oil Red O. Lipid accrual was visualized by Oil Red O staining according to previously
published protocols [26]. Briefly, cells were washed in PBS and fixed in 4% formaldehyde in
PBS (pH 7.4) for 1 h at room temperature. Cells were then rinsed in 60% isopropanol and after
drying, stained with 0.3% Oil Red O in isopropanol for 10 min at room temperature. Cells
were subsequently washed in water and images captured using a digital camera (Canon
EF-S18-55IS2).
Histological analysis of mouse bone
Mouse femurs were collected at selected time points following osteotomy and fixed in 4%
paraformaldehyde in PBS (pH 7.4) for 24 h at 4˚C. Bones were subsequently washed in run-
ning tap water and incubated in decalcifying solution consisting of 15% ethylenediaminetetra-
acetic acid (EDTA) (pH 8) with 0.5% paraformaldehyde for up to 2-weeks at 4˚C with regular
changes [39]. Once decalcified, bones were washed in running tap water overnight, processed
and embedded in paraffin wax.
Safranin O/ Fast Green. Safranin O/ Fast Green staining was used to visualize cartilagi-
nous callus formation in paraffin wax sections (8 μm) of femurs at 10, 14 and 21 days following
osteotomy. Tissue sections were dewaxed, rehydrated and stained in 0.05% Fast Green for 5
min. Slides were directly transferred to 0.1% Safranin O for 5 min and following dehydration
in graded alcohols, mounted in DPX. Images were captured using a Leica M205C stereo
microscope (Leica Microsystems, Heerbrugg, Switzerland) fitted with a digital camera (Canon
EF-S18-55IS2). The ratio of Safranin O positive area to callus area was determined using NIH
ImageJ software, where at least three serial tissue sections of the central callus region between
the inner screws from 7 to 10 mice per group were analysed.
Immunohistochemistry. Tissue sections were dewaxed, rehydrated and treated sequen-
tially with Avidin/Biotin Blocking Kit (Abcam), 3% H2O2 and normal swine serum (Reactolab,
Servion, Switzerland) to reduce non-specific staining. Sections were then incubated for 1 h at
37˚C with either polyclonal rabbit anti-HTRA1 (1:300), polyclonal rabbit anti-HTRA3 (1:400),
or equivalent dilutions of normal serum. After washing in PBS, sections were incubated with a
biotinylated swine anti-rabbit IgG (1:400) for 45 min at 37˚C followed by washing and a fur-
ther incubation for 30 min with Vectastain (Reactolab). Sections were developed using 3,3’
diaminobenzidine tetrahydrochloride (DAB) (Sigma-Aldrich), counterstained with Harris
modified hematoxylin (Sigma-Aldrich) and visualized using an Olympus BX51 light micro-
scope (Olympus Schweiz AG, Volketswil, Switzerland).
Statistical analysis
Two-tailed unpaired Student’s t-test was used for comparison of two groups, and one-way
analysis of variance (ANOVA) with Tukey’s post hoc test was used for multiple group compar-
isons. In all cases, a P-value of< 0.05 was considered statistically significant, and all data were
expressed as mean ± standard deviation (S.D.).
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Results
Loss-of-function of HTRA1 enhances osteogenic differentiation of
C3H10T1/2 cells
The multipotent mouse cell line C3H10T1/2 represents a useful tool for investigating osteo-
genesis in vitro, having the capability of simulating many of the characteristics associated with
endochondral ossification in response to BMP-2 stimulation [43, 44]. In the current report, we
used lentivirus-delivered shRNA targeting the Htra1 gene to assess the influence of loss-of-
function of HTRA1 on BMP-2-induced osteochondral differentiation of C3H10T1/2 cells over
the course of 7 weeks. We observed a time dependent increase in Htra1 expression in response
to BMP-2 in C3H10T1/2 cells treated with shRNA control vector (shControl), reaching a
maximum of 5.6-fold (± 0.5) at day 28 (Fig 1). Attempts were also made to measure Htra3
and Htra4 expression levels, but values remained below detectable limits. Transduction of
C3H10T1/2 cells with Htra1-specific shRNA (shHtra184) efficiently suppressed Htra1 gene
expression throughout the course of the study, and significantly altered the temporal gene
expression profiles of selected chondrocyte and osteogenic markers in response to BMP-2
stimulation. Expression levels of the chondrogenic markers Sox9, Acan, Col2a1 and Col10a1
were significantly reduced in shHtra184-treated cells as compared to shControl-treated cells at
the majority of time points tested. By contrast, the expression levels of several osteogenic
markers including Col1a2, Runx2, Spp1, Sparc, and most notably, Bglap and Mmp13, were sig-
nificantly enhanced at selected time points in HTRA1 deficient cells. Interestingly, BMP-2
induced Ibsp expression appeared to be delayed in HTRA1 deficient cells, and was significantly
lower than shControl-treated cells at day 21. However, by day 28, Ibsp expression levels in
shHtra184-treated cells had increased, and were significantly enhanced as compared to shCon-
trol cells.
It therefore appeared that loss of HTRA1 favoured a more osteogenic lineage commitment
of C3H10T1/2 cells in response to BMP-2. In accordance with this, Htra1 knockdown also sig-
nificantly enhanced mineralized matrix deposition at day 42 and 49 as determined by Alizarin
Red S staining (Fig 2). Similar effects were also observed when C3H10T1/2 cells were trans-
duced with an alternative Htra1-specific shRNA oligonucleotide (shHtra186) (S2 Fig). These
data therefore confirm that HTRA1 loss acts to promote C3H10T1/2 osteogenesis and matrix
mineralization.
During the course of these studies, we noticed what appeared to be adipocytes present
within C3H10T1/2 cell cultures treated with shHtra184 following 3 to 4 weeks of stimulation
with BMP-2. Indeed, Oil Red O staining confirmed the presence of numerous lipid laden cells
in C3H10T1/2 cultures transduced with shHtra184 (Fig 3A) as compared to those transduced
with shControl (Fig 3B). Furthermore, expression levels of several adipogenic markers includ-
ing Pparg, Fabp4, Cd36 and Adipog were significantly increased in shHtra184-treated cells
(Fig 3C). These results therefore demonstrated that the stimulatory effects of loss-of-function
of HTRA1 on C3H10T1/2 osteogenesis were paralleled by increases in adipocyte formation.
Bone structure and regeneration are unaffected in 16-week-old
HTRA1-deficient mice
Having identified HTRA1 as a mediator of osteochondral differentiation in vitro, we next
asked the question whether these effects were also apparent in vivo. In order to investigate this,
we used a well established Htra1-null mouse strain generated through targeted mutation of
exon 1 [22, 38]. Unexpectedly, we failed to identify any significant differences in trabecular or
cortical bone structure between the femurs of wild-type (WT), heterozygous (Htra1-HET) and
Role of HTRA1 in bone formation and regeneration
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homozygous (Htra1-KO) Htra1-knockout mice, as determined by micro-CT (Fig 4). There-
fore, it appeared that normal bone development, at least in mice, was not dependent on func-
tional HTRA1.
As with long bone development, fracture healing involves a well coordinated series of
events mediated, in part, through the actions of chondroprogenitor and osteoprogenitor cells,
culminating in the production and eventual mineralization of a hyaline cartilage matrix [45].
However, in contrast to skeletal development, bone repair relies heavily on inflammatory cues
Fig 1. Effect of Htra1 knockdown on gene expression in BMP-2 stimulated C3H10T1/2 cells. RT-qPCR
analysis was used to determine the expression levels of Htra1, Sox9, Acan, Col2a1, Col10a1, Col1a2, Runx2,
Spp1, Sparc, Ibsp, Bglap and Mmp13 in C3H10T1/2 cells transduced with non-target control shRNA
(shControl) or Htra1-specific shRNA (shHtra184) at selected time points following stimulation with rhBMP-2
(100 ng/ml). Gene expression levels were determined using the 2-ΔΔCT method and presented as fold change
relative to uninduced cells at day 0 (value = 1). All values are expressed as mean ± S.D. (triplicates).
*P < 0.05, **P < 0.01 comparison between shControl and shHtrA184 using one-way ANOVA.
https://doi.org/10.1371/journal.pone.0181600.g001
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to generate the prerequisite mesenchymal stem cell condensations responsible for initiating
the cartilaginous template and subsequent mineralized matrix [46]. Clearly, therefore, impor-
tant differences exist between bone development and repair, which could act to influence
HTRA1’s impact on new bone formation. With this in mind, we next proceeded to investigate
the effects of HTRA1 ablation on bone repair. An osteotomy defect was generated in the
femurs of WT and Htra1-KO mice, and stabilized with a flexible MouseFix plate in order to
promote endochondral ossification, and thus allow for the visualization of cartilage and bone
formation. Surgical intervention was well tolerated by both mouse strains, with no adverse
events observed, and weight loss remaining within acceptable limits (< 15% total body
weight). Histological analysis of paraffin wax tissue sections using Safranin O/ Fast green dem-
onstrated comparable amounts of cartilage callus in the osteotomy defects of WT and Htra1-
knockout mice at days 10, 14 and 21 (Fig 5A). Similarly, analysis of osteotomy defect sites at
days 21 and 35 using micro-CT identified comparable amounts of mineralized bone between
both mouse strains (Fig 5B). Additional osteotomy studies were also undertaken using a rigid
MouseFix plate in order to determine whether HTRA1 loss affected bone repair under condi-
tions more conducive to intramembranous ossification. However, bone volume within rigid
stabilized osteotomy sites was also found to be comparable between both mouse strains,
Fig 2. Effect of Htra1 knockdown on mineralized matrix production in BMP-2 stimulated C3H10T1/2
cell cultures. CH310T1/2 cells stably transduced with non-target control shRNA (shControl) or Htra1-specific
shRNA (shHtra184) were stimulated with rhBMP-2 (100 ng/ml) for up to 49 days and stained with Alizarin Red
S. The extracted dye was quantified and normalized to cell number. All values are expressed as mean ± S.D.
(triplicates). *P < 0.01, as compared to shControl using one-way ANOVA.
https://doi.org/10.1371/journal.pone.0181600.g002
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indicating that the lack of deviations in bone regeneration in Htra1-KO mice was not due to
the method of osteotomy stabilization (S3 Fig).
Immunohistological analysis of tissue sections of the osteotomy site in Htra1-KO mice
revealed positive staining for HTRA1 protein predominantly in cells surrounding the callus
cartilage at day 14 (Fig 6A), as well as in chondro-osseous transition zones at day 21 (S4A Fig).
As anticipated, HTRA1 protein was not detected in any of the tissue sections analysed from
Htra1-KO mice (Fig 6B and S4B Fig). Based on the close structural, and potentially functional
similarities between HTRA1 and HTRA3 [8], we also assessed the expression of HTRA3 in
osteotomy sites. Indeed, we could detect HTRA3 protein at day 14 and day 21 in sections from
WT (Fig 6C and S4C Fig) and Htra1-KO mice (Fig 6D and S4D Fig). Furthermore, HTRA1
and HTRA3 were detected at comparable locations in the osteotomy sites of WT mice, and in
some cases were even expressed by the same cell populations, thereby suggesting possible over-
lapping functions (inset Fig 6A and 6C; inset S4A and S4C Fig).
Fig 3. Htra1 knockdown enhances C3H10T1/2 adipogenesis. CH310T1/2 cells stably transduced with
Htra1-specific shRNA (shHtra184) (A) or non-target control shRNA (shControl) (B) were stimulated with
rhBMP-2 (100 ng/ml) for 23 days and stained with Oil Red O. Scale bar = 500 μm; inset scale bar = 25 μm. (C)
RT-qPCR was used to measure expression levels of Pparg, Fabp4, Cd36 and Adipog after 21 and 28 days
stimulation with rhBMP-2 (100 ng/ml). All values are expressed as mean ± S.D. (triplicates). *P < 0.05,
**P < 0.01 comparison between shControl and shHtrA184 using Student’s t-test.
https://doi.org/10.1371/journal.pone.0181600.g003
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HTRA1 influences the aging bone phenotype
It has previously been demonstrated that mouse embryonic fibroblasts harvested from Htra1-
KO mice are more resistant to premature cell senescence than wild-types [47], thereby provid-
ing a possible link between HTRA1 activity and age-related processes. This is further sup-
ported by the recent finding that significant increases in systemic levels of HTRA1 were
associated with increased incidences of frailty in elderly patients [48]. We therefore asked the
question whether aging had any influence on the bone phenotype of Htra1-KO mice. Indeed,
micro-CT analysis demonstrated significant improvements in trabecular and cortical parame-
ters of femurs from 52-week-old Htra1-KO mice as compared to age-matched wild-type mice
(Fig 7 and S2 Table and S5 Fig). Although significant increases in trabecular thickness were
observed in wild-type mice, trabecular spacing was found to be significantly lower in Htra1-
KO mice, thereby indicating that the improved trabecular spacing in these mice was primarily
due to increases in trabecular number.
Discussion
Despite several studies having identified HTRA1 in calcified tissue, its actual role in bone for-
mation continues to remain an enigma. In the current report, we set out to evaluate the effects
of long-term HTRA1 depletion on bone formation both in vitro and in vivo. Our findings
Fig 4. Mouse femur microstructure is unaffected by HTRA1 deficiency. Micro-CT analysis of femurs
from 16-week-old wild-type (WT, n = 8), Htra1-heterozygous (Htra1-HET, n = 8), and Htra1-knockout (Htra1-
KO, n = 7) mice. BV/TV, trabecular bone volume fraction; BS/TV, trabecular bone surface density; Tb.Th,
trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular spacing; Ct.Th, cortical thickness. All results
are expressed as mean ± S.D.
https://doi.org/10.1371/journal.pone.0181600.g004
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demonstrated that although HTRA1 deficiency had a profound effect on osteogenic lineage
commitment in vitro, it failed to influence bone structure and regeneration when assessed in
16-week-old mice. Interestingly however, significant improvements in various structural bone
parameters were observed in 52-week-old HTRA1-deficient mice as compared to age-matched
wild-type controls, thereby providing a possible link between HTRA1 expression and the bone
aging phenotype.
Indications that HTRA proteins may play a role in regulating bone formation initially came
from developmental studies performed in mice, where in situ hybridization and immunohisto-
chemical analyses identified HTRA1 and HTRA3 within bone tissue [9, 19, 49]. However, it
wasn’t until several years later that evidence emerged of a possible functional role for HTRA1
in bone formation. Studies performed using mouse-derived osteoblasts demonstrated that
despite its upregulation in response to BMP-2, HTRA1 acted as a negative regulator of bone
formation [29, 30]. Moreover, the observation that Htra1-deficient mice have a moderately
improved bone phenotype [31], suggested that HTRA1’s influence on bone may go beyond
simply affecting mineral formation in vitro. However, an equal number of studies also now
exist in which HTRA1 has been shown to have a positive influence on matrix mineralization
Fig 5. Bone repair in mice is unaffected by HTRA1 deficiency. (A) Cartilage area within osteotomy
calluses of wild-type (WT) and Htra1-knockout (Htra1-KO) mice was determined by Safranin O staining (red)
at 10 days (WT, n = 8; Htra1-KO, n = 9), 14 days (WT, n = 10; Htra1-KO, n = 7), and 21 days (WT, n = 9;
Htra1-KO, n = 7) after surgery. (B) Micro-CT evaluation of bone volume (BV) in osteotomy sites of femurs
stabilized with a flexible MouseFix plate from wild-type (WT) and Htra1-knockout (Htra1-KO) mice at 21 days
(WT, n = 11; Htra1-KO, n = 10) and 35 days (WT, n = 10; Htra1-KO, n = 13) after femoral osteotomy. All
results are expressed as mean ± S.D.
https://doi.org/10.1371/journal.pone.0181600.g005
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in vitro. We and others have previously reported that loss-of-function of HTRA1 in primary
human and mouse MSCs results in impaired osteogenic differentiation [15, 27, 28]. Further-
more, the overexpression of HTRA1, or its exogenous addition, had the capacity to signifi-
cantly enhance matrix mineralization by MSC-derived osteoblasts [15, 28]. A major difference
between these studies and those in which HTRA1 was reported to negatively influence osteo-
genesis, is that primary MSCs were used as opposed to immortalized cell lines (2T3 cells) or
long-term bone marrow cultures (KusaO cells). As such, HTRA1’s potential to modify osteo-
genic differentiation and bone mineral formation may be dependent on cell type.
In the current report, we have extended these investigations to include the murine mesen-
chymal cell line C3H10T1/2. In contrast to our previous findings, we demonstrated that loss-
of-function of HTRA1 promoted C3H10T1/2 osteogenic differentiation and matrix minerali-
zation. One possible explanation for these conflicting results is provided by the observation
that HTRA1-deficient C3H10T1/2 cells had a significantly greater tendency to undergo adipo-
genesis. In stark contrast to primary MSCs, including those derived from fat [50] and bone
[51], the osteogenic induction of C3H10T1/2 cells is positively regulated by pro-adipogenic
Fig 6. Immunostaining of HTRA1 and HTRA3 in callus tissue. Representative micrographs of anti-HTRA1
(A, B), anti-HTRA3 (C, D), or normal rabbit serum (E, F) stained paraffin wax sections of femurs from WT (A,
C, E) and Htra1-KO (B, D, F) mice 14 days after osteotomy. HTRA1 and HTRA3 staining was detected using
horseradish peroxidase-diaminobenzidine (brown) and sections counterstained with Harris modified
hematoxylin (blue). Main scale bar = 100 μm; inset scale bar = 20 μm.
https://doi.org/10.1371/journal.pone.0181600.g006
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gene expression [52]. Therefore, it’s quite possible that the stimulatory effects of HTRA1 defi-
ciency on C3H10T1/2 osteogenesis were indirectly due to increases in the expression of adipo-
genic gene markers. The concept of loss-of-function of HTRA1 favouring adipogenesis has
previously been demonstrated in human BMSCs [15, 26], although unlike HTRA1-deficient
C3H10T1/2 cells, this resulted in significant reductions in their osteogenic potential [15]. Cur-
rently, it’s unclear whether HTRA1-deficient C3H10T1/2 cells represent a heterogeneous pop-
ulation of adipocytes and osteoblasts, or if they are one in the same. Certainly, evidence does
exist to suggest that MSC-derived adipocytes have the potential to undergo transdifferentiation
into osteoblasts, and even chondrocytes [53]. Taken together, these results further exemplify
the complexities involved in trying to decipher HTRA1’s role in bone formation, and provide
additional support for the concept that its effects on osteogenic differentiation are predomi-
nantly cell-type specific.
In order to better understand the implications of HTRA1 loss on the physiology of bone
formation, several Htra1-knockout mouse models have been generated by different research
groups. However, as with the findings from studies evaluating the effects of HTRA1 loss in
vitro, results emanating from these in vivo investigations also appear to be beset by inconsisten-
cies. Graham et al (2013) observed improvements in various bone structural parameters in
Fig 7. Femur microstructure is improved in HTRA1-deficienct mice. Micro-CT analysis of femurs from
52-week-old wild-type (WT, n = 8) and Htra1-knockout (Htra1-KO, n = 6) mice. BV/TV, trabecular bone
volume fraction; BS/TV, trabecular bone surface density; Tb.Th, trabecular thickness; Tb.N, trabecular
number; Tb.Sp, trabecular spacing; Ct.Th, cortical thickness. All results are expressed as mean ± S.D.
*P < 0.05, **P < 0.01 using Student’s t-test.
https://doi.org/10.1371/journal.pone.0181600.g007
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Htra1-knockout mice as determined by micro-CT, and concluded that this was most likely
due to enhanced TGF-β signaling based on the fact that HTRA1 could cleave TGF-β receptors
[31]. However, it should be pointed out that in a more recent study by Beaufort et al [54],
HTRA1 was shown to positively regulate TGF-β pathway activation in vivo, although its influ-
ence on bone structure was not reported. Results from our own micro-CT analysis of intact
femurs taken from 16-week-old Htra1-knockout mice demonstrated their bone structure to be
comparable to that of age-matched wild-type mice. Moreover, despite confirming the presence
of HTRA1 protein within regenerating bone of wild-type mice, and its absence from Htra1-
knockout mouse tissue, bone repair also appeared to be unaffected by the loss of HTRA1.
HTRA1’s localization to, and potential involvement in, new bone formation has previously
been attested to in a recent in vivo study examining the effects of thyroxine exposure on calvar-
ial growth sites in mice, where enhanced levels of HTRA1 were identified at sites of increased
osteoblast activity [55]. We were therefore surprised not to have observed any significant devi-
ations in bone regeneration in HTRA1-deficient mice. Interestingly, immunohistochemical
staining of regenerating bone also detected HTRA3 at similar locations as HTRA1 in wild-type
mice, as well as in the callus of Htra1-knockout mice. As far as we are aware, this is the first
report of HTRA3 within bone tissue of adult mice undergoing bone repair. As with HTRA1, it
was primarily detected at the borders of cartilaginous tissue within the callus, where chondro-
cyte apoptosis and subsequent bone remodelling are thought to occur [56]. These findings
therefore signify possible functional redundancy between these two HtrA paralogs, whereby
loss of HTRA1 is compensated for by HTRA3. Further investigations into bone regeneration
using mice deficient in HTRA3, or HTRA1 and HTRA3, may help to provide additional
insights into the role of HtrA proteases in bone formation.
Previous studies have identified HTRA1 as an inducer of premature cell senescence [47],
and elevated levels of HTRA1 have been positively correlated with increased incidences of
frailty in the aged [48]. Therefore, we also considered the possibility that changes in the bone
phenotype of Htra1-knockout mice may become more apparent with aging. Indeed, the bone
structure of femurs from 52-week-old mice was significantly improved in Htra1-knockout
mice as compared to their wild-type counterparts. These findings therefore suggest that, in
mice at least, HTRA1 may represent an important determining factor for bone quality in
response to aging, and further studies examining bone regeneration in aged HTRA1-deficient
mice may be warranted. Certainly, these new findings are more in keeping with our in vitro
data, where mineralized matrix formation was enhanced in HTRA1-deficient C3H10T1/2
cells. However, there still exists the matter of reconciling these observations with the results
obtained from previous studies investigating the effects of loss or gain of HTRA1 function on
MSC lineage commitment [15, 26–28]. The choice of cell type, and preference for immortal-
ized cell line over primary cells, may have played some part in defining HTRA1 as a pro- or
anti-osteogenic mediator. Certainly, the response of cultured cells to loss of HTRA1 varies
considerably, where for instance proliferation is either decreased [57], enhanced [58], or unaf-
fected [59] depending on the cell source used. Therefore, some caution should be taken in
translating these in vitro findings to an in vivo system, where the generation of a particular phe-
notype may culminate from a series of heterogeneous cellular responses to alterations in
HTRA1 production. Taken together, our findings further identify HTRA1 as a potent regula-
tor of the multilineage differentiation potential of MSCs, and provide evidence to suggest that
although HTRA1 does not appear to influence bone development and regeneration beyond
the in vitro system, it may contribute to the aging bone phenotype in mice. Whether this also
applies to aged human bone, however, remains to be determined.
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Supporting information
S1 ARRIVE Checklist. NC3Rs ARRIVE guidelines checklist.
(PDF)
S1 Table. List of TaqMan gene expression assays used in RT-qPCR analysis.
(DOCX)
S2 Table. Full list of bone morphometric indices used in micro-CT analysis of femurs from
52-week-old mice.
(DOCX)
S1 Fig. Micro-CT analyses of bone within osteotomy site of mouse femur. Representative
images of posterior, anterior, lateral and medial aspects of an Htra1-KO mouse femur at 21
days following osteotomy. The red colouration highlights the mineralized tissue within the vol-
ume of interest (500 x 500 x 280 voxels) as observed following removal of the MouseFix plate.
(TIF)
S2 Fig. Effect of Htra1 knockdown on mineralized matrix production in BMP-2 stimulated
C3H10T1/2 cell cultures. (A) RT-qPCR analysis was used to confirm efficient knockdown of
Htra1 gene expression in C3H10T1/2 cells transduced with Htra1-specific shRNA (shHtra186)
at selected time points following stimulation with rhBMP-2 (100 ng/ml). Gene expression levels
were determined using the 2-ΔΔCT method and presented as fold change relative to uninduced
cells at day 0 (value = 1). All values are expressed as mean ± S.D. (triplicates). P< 0.01 com-
parison between shControl and shHtra186 using one-way ANOVA. (B) CH310T1/2 cells stably
transduced with non-target control shRNA (shControl) or Htra1-specific shRNA (shHtra186)
were stimulated with rhBMP-2 (100 ng/ml) for up to 42 days and stained with Alizarin Red S.
(TIF)
S3 Fig. Bone repair in mice using a rigid MouseFix plate. Micro-CT evaluation of bone vol-
ume (BV) in osteotomy sites of femurs stabilized with a rigid MouseFix plate from wild-type
(WT) (n = 9) and Htra1-knockout (Htra1-KO) (n = 9) mice at 21 days after femoral osteot-
omy. All values are expressed as mean ± S.D.
(TIF)
S4 Fig. Immunostaining of HTRA1 and HTRA3 in callus tissue at day 21. Representative
micrographs of anti-HTRA1 (A, B), anti-HTRA3 (C, D), or normal rabbit serum (E, F) stained
paraffin wax sections of femurs from WT (A, C, E) and Htra1-KO (B, D, F) mice 21 days after
osteotomy. HTRA1 and HTRA3 staining was detected using horseradish peroxidase-diamino-
benzidine (brown) and sections counterstained with Harris modified hematoxylin (blue).
Main scale bar = 50 μm; inset scale bar = 25 μm.
(TIF)
S5 Fig. Micro-CT analyses of femurs from 52-week-old WT and Htra1-KO mice. Selected
images of distal femurs from wild-type (WT) and Htra1-knockout (Htra1-KO) mice illustrat-
ing the regions from which cortical (orange) and trabecular (red) bone measurements were
taken. Images are representative of the median trabecular BV/TV value from each group.
(TIF)
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